Insight CAR-T

Development history of CAR-T cell therapy

The development of CAR-T cell therapy can be traced back to 1989, when Cross G and three other scientists first proposed the concept of "CAR". Then, in 2008, the Fred Hutchison Cancer Institute first used CAR T cells to treat B-cell lymphoma, demonstrating the safety of this therapeutic method. In 2010, the first successful case of CD19-targeting CAR-T therapy for B-cell-associated non-Hodgkin lymphoma was reported in the United States. Then in 2011, Professor Carl June's study at the University of Pennsylvania made significant progress, and Emily's successful treatment story, prompted CAR T immune cell therapy has entered a new period of explosion. In 2017, the US Food and Drug Administration (FDA) approved the marketing authorization of the first CAR T cell product Kymriah, which marked the arrival of the commercial era of CAR T cells. In the same year, Yescarta, the second CAR-T immune cell therapy product, was also approved for marketing authorization. In 2020, the FDA approved a third CAR T-cell therapy product Tecartus. In 2021, the FDA approved two CAR-T immunotherapy products, Breyanzi and Abecma, for the treatment of refractory or relapsing large B-cell lymphoma and multiple myeloma, respectively. In the same year, CDE from China also approved the marketing authorization of two CAR T immune cell therapy products from Axi-Cel and relma-cel, both for the treatment of adult patients with refractory or recurrent large B-cell lymphoma.

In 2022, the FDA approved the marketing authorization of Carvykti, a CAR-T cell therapy product targeting B cell maturation antigen (BCMA) for the treatment of relapsed or refractory multiple myeloma.

At this point, CAR T cell therapy has entered the era of cancer immunotherapy and opened a gorgeous prelude in the world.

What is CAR-T cell therapy

CAR T cell therapy, also known as Chimeric antigen receptor T cellI immunotherapy (CAR-T), is a tumor immunotherapy that uses genetic engineering to modify T cells in vitro. This allows them to specifically recognize tumor cells and inject those cells back into the patient to treat the disease.

IIT grade IND grade Clinical grade Commercial grade

CAR-T